Article

Synthesis and Characterization of Short α and β-Mixed Peptides with Excellent Anti-Lipase Activities

Naeem Ahmed [1], Sabahat Asif [2], Muhammad Arfan [1,*], Qaiser Mahmood [3], Amjad Islam [4], Mansour K. Gatasheh [5] and Muhammad Zia [6]

1 Department of Chemistry, School of Natural Sciences, National University of Sciences and Technology, Islamabad 44000, Pakistan; naeem.ahmed@sns.nust.edu.pk
2 Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore 54792, Pakistan; sabahat6512@gmail.com
3 Chemistry and Chemical Engineering Guangdong Laboratory, Shantou 515031, China; qaiser@ccelab.com.cn
4 Key Laboratory for Preparation and Application of Ordered Structured Materials of Guangdong Province, College of Chemistry and Chemical Engineering, Shantou University, Shantou 515063, China; amjad@stu.edu.cn
5 Department of Biochemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; mgatasheh@ksu.edu.sa
6 Department of Biotechnology, Quaid-i-Azam University, Islamabad 45320, Pakistan; m.zia@qau.edu.pk
* Correspondence: marfan@sns.nust.edu.pk

Abstract: Obesity is a source of significant pathologies and deadly diseases, including heart disease, diabetes, and cancer. One of the most intriguing strategies in the hunt for new anti-obesity medications is the inhibition of pancreatic lipase (PL). This study presents a novel application of short α and β-mixed peptides as pancreatic lipase inhibitors. These peptides were synthesized in the solution phase and characterized using FTIR and ^{1}H-NMR. L-proline is present in a high percentage of natural anti-lipase peptides and was used as a β-amino acid in this study to enhance anti-lipase activity and proteolytic stability. Moreover, L-α-proline was converted to β-amino acid derivatives using the Arndt–Eistert method with the advantage of stereo control at the α-carbon. The synthesized peptides with anti-lipase activity are N-Boc-β-Pro-Gly-OBz (93%), N-Boc-O-Bz-Tyr-β-Pro-β-Pro-Gly-OBz (92%), N-Boc-O-Bz-Tyr-β-Pro-COOH (91%), N-Boc-Phe-β-Pro-OCH$_3$ (90%), and N-Boc-O-Bz-Tyr-β-Pro-OCH$_3$ (89%). These peptides may function as lead molecules for further modification to more significant molecules, which can help control obesity.

Keywords: β-amino acid; α and β-hybrid/mixed peptides; Arndt–Eistert method; Wolff rearrangement; lipase; obesity

1. Introduction

Obesity is a complex disorder with excess fat deposits all over the body, especially in the abdomen. The World Health Organization (WHO) defines a person with a body mass index (BMI) equal to or greater than 25 as overweight and a BMI equal to or greater than 30 as obese. In 2021, 1.9 billion adults were heavy, and 650 million were obese. According to the global burden of disease, over 4 million people die each year due to this widespread disease [1]. Notably, obesity is a healthcare and socioeconomic disadvantage due to associated health issues. It may multiply the risk of sleep apnea, dyslipidemia, type-II diabetes, chronic renal disease, infertility, osteoarthritis, stroke, cardiovascular disease, non-alcoholic fatty liver disease, hypertension, and some forms of cancer [2,3]. Therefore, obesity control could reduce the mortality rate and occurrence of metabolic syndrome [4].

Weight management plans, specific diets like calorie restriction and intermittent fasting, weight reduction devices, weight loss medications, bariatric surgery, and liposuction are frequently available therapeutic strategies for overweight and obese people in modern society [5]. However, methods of losing weight, including liposuction or bariatric surgery,

expose patients to high risks associated with surgery and, in some circumstances, even death [6].

Isolated compounds and plant extracts from natural sources have also been reported for their pancreatic lipase inhibitory potential, including chitosan [7], dietary fibers from cholestyramine and wheat bran [8], polylysine [9], protamine [10], and soya proteins [11]. Moreover, synthetic compounds are also reported as lipase inhibitors, e.g., Oxadiazol-2-ones [12], 5,7-dichloro-1,3-benzoxazole [13], derivatives of benzimidazole [14], chalcone [15], and quinolones [16]. Many natural and synthetic pancreatic lipase inhibitors are undergoing clinical trials. Still, these have yet to enter the clinical level because results in human trials compared to in vitro or in vivo studies were not significantly effective [17].

Due to serious side effects, most lipase inhibitor drugs have been withdrawn from the market [18]. These include phentermine [19], rimonabant [20], and sibutramine [21]. Currently, orlistat [22] is the only FDA-approved drug available on the market to treat obesity. Long-term use of orlistat to treat obesity results in severe gastrointestinal side effects. These include liquid stool, diarrhea, oily spotting, flatulence, abdominal cramping, and fecal urgency [23]. Hence, novel pancreatic lipase inhibitors are urgently needed, with no severe side effects and long-term weight loss.

Recently, α-ketoamides, tripeptides, and 1,3-diketoamides have been shown as a few examples of amide functionality-based molecules with the potential for PL inhibition. Because of the higher reactivity of their carbonyl group structures with peptide functionality, they possess a more significant potential to inhibit PL. Similarly, lipase inhibitory peptides have been reported as from natural sources [24,25]. However, their progress is hindered due to increased proteolytic instability, poor bioavailability, and low yield [26].

Earlier research has proved the use of β-amino acids in peptides to design potent, selective, and stable molecules. Due to extra methylene in the backbone, α, β-mixed and β-peptides may adopt multiple conformations, may possess secondary structures, and are not identified by peptidases easily [27,28]. Hence, peptides with β-amino acids are expected to be more stable than α-peptides in vitro and in vivo.

In this study, we reported the design and synthesis of short $\alpha\beta$-mixed peptides. These peptides were synthesized through the solution phase and were evaluated for anti-lipase activity. The α-amino acid was converted to the β-amino acid derivative using the Arndt–Eistert method [29] and Wolff rearrangement [30] with the advantage of stereo control and high yield.

2. Results and Discussion

2.1. Chemistry

α-Amino acids and their derivatives, like L-proline **1**, L-phenylalanine **2**, and L-O-benzyl-protected tyrosine **3**, were treated with $(Boc)_2O$ in a water/dioxane (1:1) mixture to obtain N-Boc-L-Proline **4**, N-Boc-L-Phenylalanine **5**, and N-Boc-O-bz-Tyrosine **6**, respectively. The protection of compounds **4**–**6** was successful, indicated by characteristic bands in FTIR spectra ranging between 1666 and 1613 cm^{-1} (C=O carbamate) and between 1380 and 1361 cm^{-1} ($C(CH_3)_3$) from Boc (Scheme **1**). Compound **6** was activated with ethyl chloroformate in the presence of triethylamine and converted to diazoketone **7** via the mixed anhydride method using diazomethane [29]. With the Wolff rearrangement [30], using triethylamine, silver benzoate, and dry methanol, compound **7** was converted to β-ester **8**. The Wolff rearrangement converts the diazo molecule to a carbonyl molecule by removing nitrogen and rearranging the carbene intermediate with the retention of the configuration [31].

Scheme 1. Synthesis of Boc-Protected Amino acids.

In ^{1}HNMR spectra, a singlet at δ 6.1 ppm (-CH=N$_2$) integrated for one proton confirmed the formation of diazoketone **7**, and a singlet at δ 3.59 ppm (-OCH$_3$) combined for three protons confirmed the formation of β-methyl ester of Boc proline **8**. Compounds **8**, **8A**, and **12** were Boc-deprotected with TFA in dry DCM [32]. Compound **8** was converted to β-acid **11** by base hydrolysis, as indicated by a shift in carbonyl IR band from 1736 cm^{-1} in **8** to 1727 cm^{-1} in **11** and confirmed by the disappearance of the singlet at δ 3.59 ppm (-OCH$_3$) integrated for three protons and by the appearance of a broad singlet at δ 12.19 ppm (-COOH) in the ^{1}HNMR spectra of **8** and **11**, respectively (Scheme 2).

Scheme 2. Reagents and conditions; (i) Ethyl chloroformate, Dry Et$_3$N, Dry THF, under N$_2$, −15 °C to −5 °C, CH$_2$N$_2$ in ether, 4 h (ii) Ag+, Dry Et$_3$N, dry CH$_3$OH, −25 °C to RT, under dark, 3 h (iii) 0.75N NaOH, Dry MeOH, 0°C to RT, 3–4 h.

The synthesis of peptides **12**, **13**, **14**, and **17** was achieved using EDC as a coupling agent and HOBt in dry chloroform [33]. In the ^{1}HNMR spectrum, a singlet at δ 1.39 ppm integrated for nine protons (C(CH$_3$)$_3$) from the Boc protecting group and another singlet at δ 7.37 ppm (-NH) integrated for one proton confirmed the synthesis of dipeptide N-Boc-β-Pro-Gly-OBz **12**. A singlet at 1.38 ppm integrated for nine protons (C(CH$_3$)$_3$) and one more singlet at 3.63 ppm combined for three protons (-OCH$_3$) in the ^{1}HNMR spectrum of dipeptide **13** confirmed its synthesis. In the ^{1}HNMR spectrum, a singlet at 5.1 ppm integrated for two protons (-CH$_2$-Ar monosubstituted) and another singlet at 3.6 ppm integrated for three protons (-OCH$_3$) confirmed the synthesis of dipeptide **14**. The synthesis of tetrapeptide **17** was established by the presence of a singlet at 1.39 ppm integrated for nine protons (C(CH$_3$)$_3$) and a broad singlet at 6.95 ppm (-NH) combined for one proton in its ^{1}HNMR spectrum (Scheme 3). It is evident that our desired α, β-mixed peptides were synthesized successfully with good yield.

Scheme 3. Reagents and conditions: (i) 0.75 N NaOH, Dry MeOH, RT, 8hr; (ii) TFA, Dry DCM, RT, 6hr; (iii) EDC, HOBt, Dry TEA, Dry CHCl₃, 16hr

2.2. Pancreatic Lipase (PL) Inhibitory Activity of Peptides

Lipases are essential in maintaining lipid homeostasis and in diseases like obesity that are linked to it. They hydrolyze dietary lipids into free fatty acids and simple glycerides, which help the body absorb them. The PL, also known as triacylglycerol esterase, is one of the most essential lipases for the intestinal absorption of fatty acids. In human PL, Ser-152, His-263, and Asp-176 make up a typical catalytic triad, which is highly conserved [34]. The problem of obesity can be controlled by inhibition of PL activity. In this study, the short α, β-mixed peptides (**12**, **13**, **14**, **15**, **17**) with 2–4 amino acid residues were synthesized through the solution phase, characterized by FTIR and ^{1}HNMR spectral analysis, and for the first time screened for PL enzyme inhibition in vitro (Table 1). The results of the PL inhibition showed that all synthesized short α, β-mixed peptides were excellent inhibitors of PL, and their activity was also comparable to that of orlistat (standard drug). Peptide **12** presented the highest activity, followed by **17**, **15**, **13**, and **14** in decreasing order of inhibitory effect (92, 91, 90, and 89%, respectively). In the synthesized peptide set, **14** showed the weakest inhibitory potential (89%), 4% less than the peptide showing the

highest inhibitory potential, **12**. This suggests that α, β-mixed peptides could be a good source of enzyme inhibitory peptides.

Table 1. The anti-lipase activity of short α, β-mixed peptides.

Codes	Short α, β-Mixed Peptides	% Lipase Inhibition
12	N-Boc-β-Pro-Gly-OBz	93
13	N-Boc-Phe-β-Pro-OCH$_3$	90
14	N-Boc-O-Bz-Tyr-β-Pro-OCH$_3$	89
15	N-Boc-O-Bz-Tyr-β-Pro-COOH	91
17	N-Boc-O-Bz-Tyr-β-Pro-β-Pro-Gly-OBz	92
Standard	Orlistat	98

Published literature regarding α and β-mixed peptides as lipase inhibitors is not available. This is the first study to report α and β-mixed peptides as PL inhibitors. However, peptides incorporating β-amino acids have been reported as anti-HIV [35], anti-cancer [36], antimicrobial [37], and anti-bacterial [38]. Recently, plant sources [39,40] have been extensively studied as PL inhibitors. In addition, synthetic PL-inhibiting molecules like thiazole–benzimidazole conjugates [41], quinazolinone hybrid analogs [42], coumarin derivatives [43], indole–thiazolidinedione hybrids [44], and salicylanilides [45] have also been reported. However, numerous studies, such as (Mudgil, 2022) [25] (Ketprayoon, 2021) [46] and (Esfandi, 2021) [47], have investigated the anti-lipase activity of peptides from protein sources.

The synthetic peptides derived from β-amino acids in this study exhibited a higher activity (89 to 92%) than that found in earlier studies of α-peptides. For example, the peptides ELPPHFL, APFPLR, and LNFEPR from sea cucumber (*C. frondose*) had lipase inhibition percentages of 75, 60, and 72%, respectively [48]. The three long chemically synthesized α-peptides with 17–23 residues FFRSKLLSRGAAAAKGALLPQYW, RCMAFLLS-DGAAAAQQLLPQYW, and RPAQPNYPWTAVLVFRH from cumin seeds showed inhibition percentages of 55, 50, and 23%, respectively. Moreover, isolated α-peptides LAPSTIK and IIAPPER [49] from *Gryllodes sigillatus*, HLPGRG [25] from cow casein hydrolysates, and PAGNFLP [25] from camel casein hydrolysates also exhibited PL inhibition. Zielinska et al. reported the anti-lipase activity of peptides from the in vitro digestion of edible insects [49]. The author reported two α-peptides, ILAPPER and FDPFPK, with potent lipase inhibitory activities. Moreover, both peptides of this study have two proline residues at different positions. The author further concluded that Pro and Leu might contribute to the activity. Similarly, Zhang (2022) [48] reported that the α-peptide APFPLR, derived from sea cucumber (*C. frondose*), with Pro, Leu, and Phe residues, exhibited anti-lipase activity. The sequence of peptides synthesized in this study also has Tyr, Phe, Leu, Gly, and Pro.

The short peptides of our study showed excellent PL inhibition potency compared to α-peptides in the literature [48,50] and comparable activity to that of a standard drug (orlistat), which is encouraging. On the other hand, the long-term use of orlistat results in severe side effects [51,52]. Furthermore, the presence of the β-amino acid in our synthesized short α, β-mixed peptides can be a better choice as an anti-lipase inhibitor because the peptidic nature will result in fewer side effects. Therefore, short α and β-mixed peptides can be lead compounds for developing anti-lipase drugs more effective than drugs already present in the market with many side effects.

The significance of this work is the synthesis of short peptides with β-amino acids and their novel application as PL inhibitors. The peptides from natural sources used for comparison in this study have six to twenty-three amino acids. But peptides of this synthesis are short, with two to four amino acids, are more active, and are more economical to synthesize. Moreover, the peptides from natural sources are α- in nature with a short half-life both in vitro and in vivo [53,54].

3. Materials and Methods

3.1. General

All reagents were purchased from Sigma Aldrich (St. Louis, MO, USA)/Merck (Lowe, NJ, USA). The melting point (m.p.) was determined on a Staffordshire ST15 OSA, UK, capillary melting point apparatus. The optical rotation of the synthesized compounds was measured by using an ATAGO (Tokyo, Japan) automatic polarimeter at 589 nm and 20 °C temperature (concentration in 0.01 g/1 mL CH_3OH). FTIR analysis of the synthesized compounds was performed using Bruker Alpha Platinum-ATR (Berlin, Germany). ^1H NMR spectra were recorded using a Bruker AC 300 NMR spectrometer. CHNS analysis of all compounds was performed using a CKTC-SECHN200 CHNS analyzer. During synthesis, dry solvents were operated using the following methods:

Chloroform: To dry chloroform, 5 g of P_2O_5 was added to 100 mL of the solvent in a round-bottom flask. The mixture was refluxed for 4–5 h, and after cooling, the solvent was distilled under nitrogen.

Dichloromethane: DCM was distilled using the same method as described for chloroform.

Triethylamine**:** The required amount of triethylamine was dried by adding KOH, refluxing for 4 h, cooling to room temperature, distilling under an inert atmosphere, and storing it over KOH pellets.

Tetrahydrofuran: To dry tetrahydrofuran (THF), CaH_2 was added and drying tubewas attached to a reflux condenser. It was stirred overnight to remove as much H_2O as possible. Then, in two neck flasks, THF was collected by filtration, and benzophenone and sodium metal were added after a few intervals until the blue color persisted for a more extended period. Finally, it was distilled under nitrogen and stored over sodium wire.

Diethyl ether: Diethyl ether was dried using the same method described above for tetrahydrofuran.

Methanol: Methanol was dried by adding 5 g of Mg and turning it to 100 mL. A few crystals of iodine were added and refluxed until white turbidity appeared. After cooling, it was distilled under nitrogen and stored in a brown bottle [55].

3.2. NH₂-Group Protection of L-Amino Acids (**4–6**)

L-amino acids (**1–3**) (13.3 mmol) were dissolved in a 1:1 dioxane/water (32 mL) mixture. Then, triethylamine (1.6 eq, 21.3 mmol, 2.97 mL) was added, followed by di-tert-butyl dicarbonate (1.1 eq, 14.6 mmol, 3.19 g) at 0 °C, and the reaction mixture was stirred at room temperature for 18 h. After reaction completion, checked by TLC, the reaction mixture was concentrated. To this, ethyl acetate and water were added, and the acidic condition (pH = 1) was maintained using 1 M $KHSO_4$. After ethyl acetate extraction, the organic layer was washed with brine, dried over $MgSO_4$, and rotary evaporated to yield N-Boc-L-amino acids [56] (**4–6**).

- N-(Boc)-L-Proline (**4**)

Reaction time: 18 h; physical appearance: light-yellow crystals, Melting point: 136 °C; yield: 98%; TLC (system: 20% EtAc/n-hexane, stain: Ninhydrin); $[\alpha]_D^{25}$: +7.1° (c = 1 mg/10 mL CH_3OH); FTIR (neat, v_{max}): 2873(C-H, CH_2, str), 2968(C-H, CH_3, str), 1734(C=O, acid), 1632(C=O, carbamate), 1422(C-N, carbamate), 1361(C($CH_3)_3$), 1159(C-O) cm^{-1}. Anal. Calcd for $C_{10}H_{17}NO_4$ (215.25): C, 55.80; H, 7.96; N, 6.5. Found: C, 55.78; H, 7.98; N, 6.51.

- N-(Boc)-L-Phenylalanine (**5**)

Reaction time: 18 h; physical appearance: thick liquid; TLC (system: 30% EtAc/n-hexane, stain: Ninhydrin); yield: 92%; $[\alpha]_D^{25}$: +25° (c = 1 mg/mL CH_3OH); FTIR (neat, v_{max}): 3330(sec. N-H, str), 3050(Ar-C=CH), 2979(C-H, CH_3, str), 2930(C-H, CH_2, str), 1714(C=O acid), 1454(Ar-C=C), 1403(C-N, carbamate), 1368(C($CH_3)_3$), 1279(C-O, acid), 1155(C-O, carbamate) cm^{-1}. Anal. Calcd for $C_{14}H_{19}NO_4$ (265.13): C, 63.38; H, 7.22; N, 5.28. Found: C, 63.37; H, 7.25; N, 5.27.

- N-Boc-O-Bn-L-Tyr (**6**)

Reaction time: 18 h; physical appearance: thick brown gel; yield: 97%; TLC (system: 30% EtAc/ n-hexane, stain: Ninhydrin); $[\alpha]_D^{25}$: +27° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v$_{max}$): 3262(sec. N-H, str), 3400–3200(O-H, acid), 3050(Ar-C=CH), 2978(C-H, CH$_2$, str), 2930(C-H, CH$_3$, str), 1613(C=O, carbamate), 1453(Ar-C=C), 1380(C(CH$_3$)$_3$), 1248(C-O, acid), 1155(C-O, carbamate)cm^{-1}. Anal. Calcd for C$_{21}$H$_{25}$NO$_5$ (371.43): C, 67.91; H, 6.78; N, 3.77. Found: C, 67.87; H, 6.76; N, 3.76.

3.3. Generation of Diazomethane Ethereal Solution

The mini diazald apparatus from Aldrich was used to generate diazomethane from diazald. This apparatus is a single compact condenser, a reaction vessel with a receiver, and an additional funnel (with clear-seal joints). The cold finger is a unique feature of this apparatus; when filled with isopropyl alcohol/liquid nitrogen slush, it prevents the escape of diazomethane and ether into the environment efficiently.

The condenser was filled with isopropyl alcohol and liquid nitrogen to make slush to liquefy the generated diazomethane ether solution. Then, the condenser was attached to the receiving flask (with clear-seal joints) and cooled in an isopropyl alcohol/liquid nitrogen bath. A reaction vessel containing potassium hydroxide solution was supplemented with ether (10 mL) and 2-(2-ethoxyethoxy) ethanol (16 mL). Over the reaction vessel, a separatory funnel was attached (with clear-seal joints) and charged with a solution of diazald (5 g, 23 mmol) in ether (40 mL). The reaction vessel was warmed to 65 °C in a water bath, and diazald solution was added for over 40 min. The rates of addition and distillation were approximately kept the same. In addition, 20 mL of diethyl ether was added after the diazald was completely used, and the distillation continued until the distillate was colorless [57].

3.4. Synthesis of N-Boc-Proline Diazoketone (**7**)

Boc-L-Proline (**7**) (6.9 mmol, 1.5 g) was dissolved in dry distilled THF (34.9 mL), followed by the addition of Et$_3$N (1.2 eq, 8.4 mmol, 1.2 mL). Ethyl chloroformate (1.5 eq, 10.5 mmol, 1 mL) was added, stirred at −15 °C under N$_2$ for 20 min, and then treated with CH$_2$N$_2$ solution in ether. The solvent was evaporated, and the reaction mixture was dissolved in ethyl acetate. It was further washed with concentrated NaHCO$_3$, NH$_4$Cl, and NaCl solutions. The organic layer was evaporated under a vacuum to obtain impure Boc-Pro diazoketone as a dark-yellow gel. It was further purified by column chromatography using an eluent (7% ethyl acetate and n-hexane) to obtain pure Boc-Pro diazoketone (**7**) as a yellow gel.

Reaction time: 5 h; physical appearance: yellow gel; yield: 74%; TLC (system: 30% EtAc/n-hexane, stain: Ninhydrin); $[\alpha]_D^{25}$: −11.2° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v$_{max}$): 2974(C-H, CH$_3$, str), 2971(C-H, CH$_2$, str), 2105(-C=N$_2$), 1680(C=O, carbamate), 1626(N-H, bending) 1360(C(CH$_3$)$_3$), 1155(C-O) cm^{-1}. ^{1}H NMR (300MHz, DMSO): δ 6.1 (1H, bs), 4.17 (1H, dd, J = 9.6, 7.5 Hz), 3.30–3.29 (2H, m), 2.15–2.10 (1H, m), 1.81–1.78 (3H, m), 1.33 (9H, s) ppm. Anal. Calcd for C$_9$H$_{14}$N$_3$O$_3^+$ (212.23): C, 50.94; H, 6.65; N, 19.80. Found: C, 50.9; H, 6.68; N, 19.85.

3.5. Synthesis of N-Boc-Pro-β-Methyl Ester (**8**)

Boc-Pro diazoketone (**11**) (2.1 mmol, 0.5 g) was dissolved in dry CH$_3$OH (6.16 mL) and then under N$_2$ at −25 °C in dark silver benzoate (0.15 eq, 0.23 mmol, 0.053 g) dissolved in triethylamine (2.9 eq, 6.1 mmol, 0.8 mL) was added. After 3 h, the rotary reaction mixture evaporated, and the residue was dissolved in ethyl acetate. The organic layer was washed with NaHCO$_3$, NH$_4$Cl, and NaCl solutions, dried over MgSO$_4$, and evaporated. The crude product was purified by column chromatography using a 15% n-hexane/ethyl acetate solvent system [30].

Reaction time: 8 h; appearance: thick white gel; yield: 95%; TLC (system: 20% EtAc/n-hexane, stain: Ninhydrin); $[\alpha]_D^{25}$: −11.2° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v$_{max}$):

2973(sec. N-H, str), 2956(C-H, CH$_3$, str), 2873(C-H, CH$_2$, str), 1736(C=O, ester), 1688(C=O, carbamate), 1460(Ar-C=C), 1365(C(CH$_3$)$_3$), 1161(C-O) cm^{-1}. ^{1}H NMR (300 MHz, DMSO): δ 4.00–3.97 (1H, m), 3.59 (3H, s), 3.33–3.19 (2H, m), 2.72–2.65 (1H, m), 2.37 (2H d, *J* = 9.3 Hz), 1.80–1.60 (3H, m), 1.39 (9H, s) ppm. Anal. Calcd for C$_{12}$H$_{21}$NO$_4$ (243.30): C, 59.24; H, 8.70; N, 5.76. Found: C, 59.21; H, 8.72; N, 5.74.

3.6. Boc-Deprotection of N-Boc-Amino Ester (9) and (10)

At 0 °C, N-Boc-Proline-β-methyl ester (1.23 mmol, 300 mg) was dissolved in dry dichloromethane (7 mL) under an inert atmosphere. After the addition of trifluoroacetic acid (TFA) (5.5 eq, 6.34 mmol, 0.52 mL), the reaction mixture was stirred for 3 h. After reaction completion, the solvent was evaporated to obtain the product [32].

3.7. Boc-Deprotection of N-Boc-Peptide Ester (16)

Under an inert atmosphere, N-Boc-β-Pro-α-Gly-OBn (500 mg, 1.049 mmol) was dissolved in dry DCM (6 mL) at 0 °C. Then, trifluoroacetic acid (TFA) (8.5 eq, 5.770 mmol, 0.44 mL) was added to the reaction mixture for 5 h. TLC indicated reaction completion, and rotary evaporation gave the final product [32].

3.8. Synthesis of N-Boc-β-Amino Acid (11)

At 0 °C, fully protected N-Boc-Proline-β-Methyl Ester was dissolved in MeOH and treated with 0.75 N NaOH (2 eq) solution portion-wise for 30 min. The reaction was completed in 8 h, as checked by TLC. The mixture was adjusted to pH 2–3 with 1 N HCl, extracted with ethyl acetate, dried over MgSO$_4$, and evaporated until dryness [29].

- (N-Boc-L-Proline-β-Acid) (11)

Reaction time: 10 h; physical appearance: white crystalline solid; melting point: 98° C; yield: 95%; TLC (system: 30% EtAc,/n-hexane, stain: Ninhydrin); [α]$_D^{25}$: −26° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v$_{max}$): 2973(sec. N-H, str), 2919(C-H, CH$_3$, str), 2873(C-H, CH$_2$, str), 1727(C=O, acid), 1650(C=O, carbamate), 1361(C(CH$_3$)$_3$), 1159(C-O) cm^{-1}. ^{1}H NMR (300 MHz, DMSO): δ 12.19 (1H, bs), 3.91 (1H, dt, *J* = 8.7 Hz), 3.33 (2H, dd, *J* = 11.4, 3.5 Hz), 2.65–2.55 (1H, m), 2.26–2.16 (1H, m), 2.14–1.99 (1H, m), 1.97–1.94 (2H, m), 1.39 (9H, s) ppm. Anal. Calcd for C$_{11}$H$_{19}$NO$_4$ (229.28): C, 57.63; H, 8.35; N, 6.11 Found: C, 57.61; H, 8.32; N, 6.09.

3.9. Synthesis of N-Boc-Peptide Acid (15)

To dry methanol, a fully protected N-Boc-peptide-β-methyl ester was added at 0 °C. In this mixture, 0.75 N NaOH (4.0 eq) solution was added in 30 min. The TLC indicated the completion of the reaction in 8 h, and then the reaction mixture was adjusted to pH 2–3 with 1 N HCl, and the product was extracted in ethyl acetate, dried over MgSO$_4$, and finally evaporated to dryness [29].

3.10. General Procedure for the Synthesis of Short α,β-Mixed Peptides (12–14)

N-Boc β-amino acid was dissolved in dry CHCl$_3$ (8 mL) and was treated with HOBt (1.2 eq, 1.25 mmol, 0.17 g) and EDC (1.2 eq, 1.25 mmol, 0.19 g). Boc-deprotected amino acid trifluoro acetate (1.04 mmol) was separately dissolved in dry chloroform (7 mL) at 0 °C under N$_2$. Then, Et$_3$N (6 eq, 11.6 mmol, 1.6 mL) was periodically added to it with constant stirring at 0 °C. Two solutions were then mixed, the reaction mixture was stirred for 16 h at room temperature, and reaction progress was monitored through TLC. After complete conversion, chloroform was added, and the organic layer was washed with 1 N HCl, NaHCO$_3$, and NaCl and then dried over MgSO$_4$ and rotary evaporated to give the respective peptides.

- Dipeptide (N-Boc-β-Pro-α-Gly-OBn) (12)

Reaction time: 16 h; physical appearance: light-yellow thick gel; yield: 75%; TLC (system: 3% CH$_3$OH/CHCl$_3$, stain: Ninhydrin); [α]$_D^{25}$: −26° (c = 2 mg/mL CH$_3$OH); FTIR

(neat, v_{max}): 3306(sec. N-H, str), 3050(Ar-C=CH), 2966(C-H, CH_3, str), 2875(C-H, CH_2, str), 1748(C=O ester), 1668(C=O, amide), 1541(N-H, bend, amide), 1455(Ar-C=C), 1394(CH_3, bend), 1365(C(CH_3)$_3$), 1255(C-O, ester), 1188(C-O, carbamate), 973(C-H, bend, mono sub), 915(C-H, bend, mono sub)cm^{-1}. ^{1}H NMR (300 MHz, DMSO): δ 8.37–8.35 (4H, m), 7.37 (1H, s), 5.125 (2H, s), 3.96 (2H, s), 3.96 (3H, d, *J* = 6.3 Hz), 3.4 (1H, bs), 3.33 (2H, d, *J* = 0.9 Hz), 3.30 (2H, d, *J* = 6.9 Hz), 1.9–1.6 (4H, m), 1.39 (9H, s) ppm. Anal. Calcd for $C_{20}H_{28}N_5O_5$ (376.45): C, 63.81; H, 7.50; N, 7.44. Found: C, 63.80; H, 7.51; N, 7.43.

- Dipeptide (N-Boc-α-Phe-β-Pro-OCH$_3$) (**13**)

Reaction time: 12 h; physical appearance: white thick gel; yield: 70%; TLC (system: 3% CH$_3$OH/CHCl$_3$, stain: Ninhydrin); $[\alpha]_D^{25}$: −6° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v_{max}): 3300(sec. N-H, str), 2974(C-H, CH_3, str), 2875(C-H, CH_2, str), 1705(C=O ester), 1634(C=O, amide), 1500(N-H, bend, amide), 1434(Ar-C=C), 1365(C(CH_3)$_3$), 1247(C-O, ester), 1162(C-O, carbamate)cm^{-1}. ^{1}H NMR(300 MHz, CDCl$_3$): δ 7.3–7.25 (5H, m), 6.2 (1H, bs), 4.6 (1H, dd, *J* = 7.5 Hz), 4.34 (1H, t, *J* = 9 Hz), 3.63 (3H,s), 3.18–3.10 (1H, m), 3.05–2.94 (1H, m), 2.91 (2H, d, *J* = 3.6 Hz), 2.86 (2H, d, *J* = 3 Hz), 2.17–2.07 (3H, m), 1.82–1.80 (1H, d, *J* = 3.9 Hz), 1.38 (9H, s) ppm. Anal. Calcd for $C_{21}H_{30}N_2O_5$ (390.48): C, 64.60; H, 7.74; N, 7.17. Found: C, 64.62; H, 7.75; N, 7.18.

- Dipeptide (N-Boc-O-Bn-α-Tyr-β-Pro-OCH$_3$) (**14**)

Reaction time: 16 h; physical appearance: brown thick gel; yield: 72%; TLC (system: 3% CH$_3$OH/CHCl$_3$, stain: Ninhydrin); $[\alpha]_D^{25}$: +0.92° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v_{max}): 3020(Ar-C=CH), 2927(C-H, CH_3, str), 2875(C-H, CH_2, str), 1733(C=O ester), 1635(C=O, amide), 1510(N-H, bend, amide), 1435(Ar-C=C), 1366(C(CH_3)$_3$), 1240(C-O, ester), 1165(C-O, carbamate), 800(para substitution)cm^{-1}. ^{1}HNMR (300 MHz,CDCl$_3$): δ 7.79–7.76 (2H, m), 7.69–7.66 (2H, m), 7.5–7.3 (5H, m), 6.96 (1H, bs), 5.13 (2H, s), 4.48–4.44 (1H, t, *J* = 7.2 Hz), 4.27–4.20 (1H, m), 3.65 (3H, s), 3.66–3.65 (1H, m), 3.63–3.60 (1H, m), 2.89 (2H, d, *J* = 3.6 Hz), 2.87 (2H, d, *J* = 3 Hz), 2.1–2.05 (4H, m), 1.38 (9H, s) ppm. Anal. Calcd for $C_{28}H_{36}N_2O_6$ (496.60): C, 67.72; H, 7.31; N, 5.64. Found: C, 67.73; H, 7.32; N, 5.63.

3.11. Tetrapeptide (N-Boc-O-Bn-α-Tyr-β-Pro-β-Pro-α-Gly-OBn) (17)

Reaction time: 16 h; physical appearance: brown thick gel; yield: 70%; TLC (system: 10% CH$_3$OH/CHCl$_3$, stain: Ninhydrin); $[\alpha]_D^{25}$: +40.59° (c = 2 mg/mL CH$_3$OH); FTIR (neat, v_{max}): 3000(Ar-C=CH), 2921(C-H, CH_2, str), 2852(C-H, CH_3, str), 1733(C=O ester), 1615(C=O, amide), 1510(N-H, bend, amide), 1455(Ar-C=C), 1377(C(CH_3)$_3$), 1240(C-O, ester), 1168(C-O, carbamate), 742(CH_2, mono-substitution)cm^{-1}. ^{1}HNMR (300 MHz, CDCl$_3$): δ 7.92 (2H, d, *J* = 8.4 Hz), 7.72 (2H, d, *J* = 8.5 Hz), 7.53–7.32 (6H, m), 7.22–7.19 (2H, m), 7.20 (1H, bs), 6.95 (1H, bs), 5.16 (2H, s), 5.13 (2H, s), 4.52–4.47 (1H, t, *J* = 7.5 Hz), 4.3–4.2 (2H, m), 4.09 (2H, s), 3.27–2.99 (10H, m), 2.1–2.05 (8H, m), 1.39 (9H, s) ppm. Anal. Calcd for $C_{28}H_{36}N_2O_6$ (496.60): C, 67.72; H, 7.31; N, 5.64. Found: C, 67.73; H, 7.32; N, 5.63.

4. Lipase Inhibition Assay

Lipase inhibition was performed to assess the anti-lipase activity. The lipase was taken in ultra-pure water (10 mg/mL) and centrifuged for 5 min at 16,000 rpm, and the fresh enzyme was made from its supernatant. The substrate utilized was olive oil. Sequentially, buffer (350 μL), lipase (150 μL), and test samples (50 μL) were added to Eppendorf tubes. To start the reaction, olive oil (450 μL) was introduced, and orlistat was used as a blocking agent. An Eppendorf tube with no sample, having a buffer, lipase, and substrate, functioned as a blank. The samples were incubated for 2 h at 37 °C and centrifuged for 1 min at 16,000 rpm; then, mixtures were taken in a 96-well plate, and at 400 nm, absorbance was measured as compared to standard (orlistat). The following formula was used to calculate the percentage of enzyme inhibition [58]:

$$\% \text{ Enzyme Inhibition} = \text{OD (b)} - \text{OD (s)} \div \text{OD (b)} \times 100$$

where OD (b) = Absorbance value of blank; OD (s) = Absorbance of the test sample.

References

1. Chia, T.Y.; Gan, C.-Y.; Shafie, M.H.; Yap, P.G.; Rodhi, A.M.; Ahmad, A.; Murugaiyah, V.; Abdulla, M.H.; Johns, E.J. A comprehensive review on the pancreatic lipase inhibitory peptides: A future anti-obesity strategy. *Electron. J. Gen. Med.* **2023**, *20*, em470. [CrossRef] [PubMed]
2. Bray, G.A.; Heisel, W.E.; Afshin, A.; Jensen, M.D.; Dietz, W.H.; Long, M.; Kushner, R.F.; Daniels, S.R.; Wadden, T.A.; Tsai, A.G.; et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. *Endocr. Rev.* **2018**, *39*, 79–132. [CrossRef]
3. Liu, T.-T.; Liu, X.-T.; Chen, Q.-X.; Shi, Y. Lipase Inhibitors for Obesity: A Review. *Biomed. Pharmacother.* **2020**, *128*, 110314. [CrossRef]
4. Dietz, W.H.; Baur, L.A.; Hall, K.; Puhl, R.M.; Taveras, E.M.; Uauy, R.; Kopelman, P. Management of obesity: Improvement of health-care training and systems for prevention and care. *Lancet* **2015**, *385*, 2521–2533. [CrossRef]
5. Jensen, M.D.; Ryan, D.H.; Apovian, C.M.; Ard, J.D.; Comuzzie, A.G.; Donato, K.A.; Hu, F.B.; Hubbard, V.S.; Jakicic, J.M.; Kushner, R.F.; et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation* **2014**, *129*, S102–S138. [CrossRef] [PubMed]
6. Krentz, A.J.; Fujioka, K.; Hompesch, M. Evolution of pharmacological obesity treatments: Focus on adverse side-effect profiles. *Diabetes Obes. Metab.* **2016**, *18*, 558–570. [CrossRef]
7. Sumiyoshi, M.; Kimura, Y. Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. *J. Pharm. Pharmacol.* **2006**, *58*, 201–207. [CrossRef] [PubMed]
8. Lairon, D.; Lafont, H.; Vigne, J.-L.; Nalbone, G.; Léonardi, J.; Hauton, J.C. Effects of dietary fibers and cholestyramine on the activity of pancreatic lipase in vitro. *Am. J. Clin. Nutr.* **1985**, *42*, 629–638. [CrossRef]
9. Tsujita, T.; Takaichi, H.; Takaku, T.; Aoyama, S.; Hiraki, J. Antiobesity action of ε-polylysine, a potent inhibitor of pancreatic lipase. *J. Lipid Res.* **2006**, *47*, 1852–1858. [CrossRef]
10. Tsujita, T.; Matsuura, Y.; Okuda, H. Studies on the inhibition of pancreatic and carboxylester lipases by protamine. *J. Lipid Res.* **1996**, *37*, 1481–1487. [CrossRef]
11. Roy, D.M.; Schneeman, B.O. Effect of soy protein, casein and trypsin inhibitor on cholesterol, bile acids and pancreatic enzymes in mice. *J. Nutr.* **1981**, *111*, 878–885. [CrossRef]
12. Point, V.; Pavan Kumar, K.V.P.; Marc, S.; Delorme, V.; Parsiegla, G.; Amara, S.; Carrière, F.; Buono, G.; Fotiadu, F.; Canaan, S.; et al. Analysis of the discriminative inhibition of mammalian digestive lipases by 3-phenyl substituted 1,3,4-oxadiazol-2(3H)-ones. *Eur. J. Med. Chem.* **2012**, *58*, 452–463. [CrossRef]
13. Jayanna, N.D.; Vagdevi, H.M.; Dharshan, J.C.; Prashith Kekuda, T.R.; Hanumanthappa, B.C.; Gowdarshivannanavar, B.C. Synthesis and Biological Evaluation of Novel 5,7-Dichloro-1,3-benzoxazole Derivatives. *J. Chem.* **2013**, *2013*, 864385. [CrossRef]
14. Kahveci, B.; Menteşe, E.; Özil, M.; Ülker, S.; Ertürk, M. An efficient synthesis of benzimidazoles via a microwave technique and evaluation of their biological activities. *Monatshefte Chem.-Chem. Mon.* **2013**, *144*, 993–1001. [CrossRef]
15. Huo, P.C.; Hu, Q.; Shu, S.; Zhou, Q.H.; He, R.J.; Hou, J.; Guan, X.Q.; Tu, D.Z.; Hou, X.D.; Liu, P.; et al. Design, synthesis, and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors. *Bioorg. Med. Chem.* **2021**, *29*, 115853. [CrossRef] [PubMed]
16. Al-Hiari, Y.M.; Kasabri, V.N.; Shakya, A.K.; Alzweiri, M.H.; Afifi, F.U.; Bustanji, Y.K.; Al-Masri, I.M. Fluoroquinolones: Novel class of gastrointestinal dietary lipid digestion and absorption inhibitors. *Med. Chem. Res.* **2014**, *23*, 3336–3346. [CrossRef]
17. Seyedan, A.; Alshawsh, M.A.; Alshagga, M.A.; Koosha, S.; Mohamed, Z. Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase: A Review. *Evid.-Based Complement. Altern. Med.* **2015**, *2015*, 973143. [CrossRef] [PubMed]
18. Kang, J.G.; Park, C.Y. Anti-Obesity Drugs: A Review about Their Effects and Safety. *Diabetes Metab. J.* **2012**, *36*, 13–25. [CrossRef] [PubMed]

19. Glazer, G. Long-term pharmacotherapy of obesity 2000: A review of efficacy and safety. *Arch. Intern. Med.* **2001**, *161*, 1814–1824. [CrossRef] [PubMed]

20. Christensen, R.; Kristensen, P.K.; Bartels, E.M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. *Lancet* **2007**, *370*, 1706–1713. [CrossRef]

21. James, W.P.T.; Caterson, I.D.; Coutinho, W.; Finer, N.; Van Gaal, L.F.; Maggioni, A.P.; Torp-Pedersen, C.; Sharma, A.M.; Shepherd, G.M.; Rode, R.A. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N. Engl. J. Med.* **2010**, *363*, 905–917. [CrossRef]

22. Ballinger, A.; Peikin, S.R. Orlistat: Its current status as an anti-obesity drug. *Eur. J. Pharmacol.* **2002**, *440*, 109–117. [CrossRef] [PubMed]

23. Chaput, J.-P.; St-Pierre, S.; Tremblay, A. Currently available drugs for the treatment of obesity: Sibutramine and orlistat. *Mini Rev. Med. Chem.* **2007**, *7*, 3–10. [CrossRef] [PubMed]

24. Garzón, A.G.; Cian, R.E.; Aquino, M.E.; Drago, S.R. Isolation and identification of cholesterol esterase and pancreatic lipase inhibitory peptides from brewer's spent grain by consecutive chromatography and mass spectrometry. *Food Funct.* **2020**, *11*, 4994–5003. [CrossRef] [PubMed]

25. Mudgil, P.; Baba, W.N.; Kamal, H.; FitzGerald, R.J.; Hassan, H.M.; Ayoub, M.A.; Gan, C.Y.; Maqsood, S. A comparative investigation into novel cholesterol esterase and pancreatic lipase inhibitory peptides from cow and camel casein hydrolysates generated upon enzymatic hydrolysis and in-vitro digestion. *Food Chem.* **2022**, *367*, 130661. [CrossRef] [PubMed]

26. Otvos, L.; Wade, J.D. Current challenges in peptide-based drug discovery. *Front. Chem.* **2014**, *2*, 62. [CrossRef]

27. Cabrele, C.; Martinek, T.A.; Reiser, O.; Berlicki, Ł. Peptides containing β-amino acid patterns: Challenges and successes in medicinal chemistry. *J. Med. Chem.* **2014**, *57*, 9718–9739. [CrossRef] [PubMed]

28. Fülöp, F.; Martinek, T.A.; Tóth, G.K. Application of alicyclic β-amino acids in peptide chemistry. *Chem. Soc. Rev.* **2006**, *35*, 323–334. [CrossRef] [PubMed]

29. Bodanszky, M.; Bodanszky, A. *The Practice of Peptide Synthesis*; Springer: Berlin/Heidelberg, Germany, 1984.

30. Meier, H.; Zeller, K.P. The Wolff rearrangement of α-diazo carbonyl compounds. *Angew. Chem. Int. Ed. Engl.* **1975**, *14*, 32–43. [CrossRef]

31. Kirmse, W. 100 Years of the Wolff Rearrangement. *Eur. J. Org. Chem.* **2002**, *2002*, 2193–2256. [CrossRef]

32. Bose, D.S.; Lakshminarayana, V. Lewis acid-mediated selective removal of N-tert-butoxycarbonyl protective group (t-Boc). *Synthesis* **1999**, *1999*, 66–68. [CrossRef]

33. Carter, J.D.; LaBean, T.H. Coupling strategies for the synthesis of peptide-oligonucleotide conjugates for patterned synthetic biomineralization. *J. Nucleic Acids* **2011**, *2011*, 926595. [CrossRef]

34. Tian, Y.; Liu, C.; Wang, S.; Du, M.; Zhu, B. Efficient screening of pancreatic lipase inhibitors from cod meat hydrolysate through ligand fishing strategy. *Front. Nutr.* **2022**, *9*, 969558. [CrossRef]

35. Takashiro, E.; Hayakawa, I.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Ozawa, Y.; Yagi, R.; Yamamoto, I.; Shibayama, T.; Nakagawa, A.; et al. Structure–activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site. *Bioorg. Med. Chem.* **1999**, *7*, 2063–2072. [CrossRef] [PubMed]

36. Tørfoss, V.; Isaksson, J.; Ausbacher, D.; Brandsdal, B.-O.; Flaten, G.E.; Anderssen, T.; Cavalcanti-Jacobsen, C.d.A.; Havelkova, M.; Nguyen, L.T.; Vogel, H.J.; et al. Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β2,2-amino acid. *J. Pept. Sci.* **2012**, *18*, 609–619. [CrossRef] [PubMed]

37. Lee, M.-R.; Raman, N.; Gellman, S.H.; Lynn, D.M.; Palecek, S.P. Incorporation of β-Amino Acids Enhances the Antifungal Activity and Selectivity of the Helical Antimicrobial Peptide Aurein 1.2. *ACS Chem. Biol.* **2017**, *12*, 2975–2980. [CrossRef] [PubMed]

38. Wani, N.A.; Singh, G.; Shankar, S.; Sharma, A.; Katoch, M.; Rai, R. Short hybrid peptides incorporating β- and γ-amino acids as antimicrobial agents. *Peptides* **2017**, *97*, 46–53. [CrossRef] [PubMed]

39. Huang, H.; Han, M.-H.; Gu, Q.; Wang, J.-D.; Zhao, H.; Zhai, B.-W.; Nie, S.-M.; Liu, Z.-G.; Fu, Y.-J. Identification of pancreatic lipase inhibitors from Eucommia ulmoides tea by affinity-ultrafiltration combined UPLC-Orbitrap MS and in vitro validation. *Food Chem.* **2023**, *426*, 136630. [CrossRef] [PubMed]

40. Deora, N.; Venkatraman, K. Lipase activity inhibited by aloenin A: Glycoside from *Aloe vera* (L.) Burm. f.—In vitro and molecular docking studies. *J. Mol. Recognit.* **2023**, *36*, e3002. [CrossRef] [PubMed]

41. Abouzied, A.; Break, M.; Huwaimel, B.; Hussein, W.; Alafnan, A.; Younes, K.; Amr, S.; Abouzied, A. Discovery of A Novel Synthetic Thiazole-benzimidazole Conjugate that Acts as a Potent Pancreatic Lipase Inhibitor using in silico and in vitro Approaches CC-BY 4.0. *Indian J. Pharm. Educ.* **2023**, *57*, 218–227. [CrossRef]

42. George, G.; Yadav, N.; Auti, P.S.; Paul, A.T. Molecular modelling, synthesis and in vitro evaluation of quinazolinone hybrid analogues as potential pancreatic lipase inhibitors. *J. Biomol. Struct. Dyn.* **2023**, *41*, 9583–9601. [CrossRef] [PubMed]

43. Yadav, N.; Paul, A.T. Synthesis of amide warhead containing coumarin derivatives as potential pancreatic lipase inhibitors: In silico and in vitro evaluation for obesity treatment. *Med. Chem. Res.* **2023**, *32*, 2219–2233. [CrossRef]

44. George, G.; Auti, P.S.; Sengupta, P.; Yadav, N.; Paul, A.T. Synthesis, molecular modelling and pharmacological evaluation of novel indole-thiazolidinedione based hybrid analogues as potential pancreatic lipase inhibitors. *J. Biomol. Struct. Dyn.* **2023**, *14*, 1–20. [CrossRef]

45. Zhao, Y.; Zhang, M.; Hou, X.; Han, J.; Qin, X.; Yang, Y.; Song, Y.; Liu, Z.; Zhang, Y.; Xu, Z.; et al. Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase. *Bioorg. Med. Chem.* **2023**, *91*, 117413. [CrossRef]

46. Ketprayoon, T.; Noitang, S.; Sangtanoo, P.; Srimongkol, P.; Saisavoey, T.; Reamtong, O.; Choowongkomon, K.; Karnchanatat, A. An in vitro study of lipase inhibitory peptides obtained from de-oiled rice bran. *RSC Adv.* **2021**, *11*, 18915–18929. [CrossRef]

47. Esfandi, R.; Seidu, I.; Willmore, W.; Tsopmo, A. Antioxidant, pancreatic lipase, and α-amylase inhibitory properties of oat bran hydrolyzed proteins and peptides. *J. Food Biochem.* **2022**, *46*, e13762. [CrossRef] [PubMed]

48. Zhang, Y.; He, S.; Rui, X.; Simpson, B.K. Interactions of C. frondosa-derived inhibitory peptides against angiotensin I-converting enzyme (ACE), α-amylase and lipase. *Food Chem.* **2022**, *367*, 130695. [CrossRef]

49. Zielińska, E.; Karaś, M.; Baraniak, B.; Jakubczyk, A. Evaluation of ACE, α-glucosidase, and lipase inhibitory activities of peptides obtained by in vitro digestion of selected species of edible insects. *Eur. Food Res. Technol.* **2020**, *246*, 1361–1369. [CrossRef]

50. Siow, H.-L.; Choi, S.-B.; Gan, C.-Y. Structure–activity studies of protease activating, lipase inhibiting, bile acid binding and cholesterol-lowering effects of pre-screened cumin seed bioactive peptides. *J. Funct. Foods* **2016**, *27*, 600–611. [CrossRef]

51. Vermaak, I.; Viljoen, A.M.; Hamman, J.H. Natural products in anti-obesity therapy. *Nat. Prod. Rep.* **2011**, *28*, 1493–1533. [CrossRef]

52. Filippatos, T.D.; Derdemezis, C.S.; Gazi, I.F.; Nakou, E.S.; Mikhailidis, D.P.; Elisaf, M.S. Orlistat-Associated Adverse Effects and Drug Interactions. *Drug Saf.* **2008**, *31*, 53–65. [CrossRef] [PubMed]

53. Pei, J.; Gao, X.; Pan, D.; Hua, Y.; He, J.; Liu, Z.; Dang, Y. Advances in the stability challenges of bioactive peptides and improvement strategies. *Curr. Res. Food Sci.* **2022**, *5*, 2162–2170. [CrossRef] [PubMed]

54. Chakrabarti, S.; Guha, S.; Majumder, K. Food-derived bioactive peptides in human health: Challenges and opportunities. *Nutrients* **2018**, *10*, 1738. [CrossRef] [PubMed]

55. Morgan, E.D. *Vogel's Textbook of Practical Organic Chemistry*, 5th ed.; Endeavour: London, UK, 1990; Volume 14, p. 148.

56. Chankeshwara, S.V.; Chakraborti, A.K. Catalyst-free chemoselective N-tert-butyloxycarbonylation of amines in water. *Org. Lett.* **2006**, *8*, 3259–3262. [CrossRef]

57. Deming, T.J. *The Practice of Peptide Synthesis*; Bodansky, M., Bodansky, A., Eds.; Springer: New York, NY, USA, 1995; Volume 33, p. 2289.

58. Asghar, M.; Sajjad, A.; Hanif, S.; Ali, J.S.; Ali, Z.; Zia, M. Comparative analysis of synthesis, characterization, antimicrobial, antioxidant, and enzyme inhibition potential of roses petal based synthesized copper oxide nanoparticles. *Mater. Chem. Phys.* **2022**, *278*, 125724. [CrossRef]